ArticleDrug safety2008
Role of cytochrome P450 polymorphisms in the development of pulmonary drug toxicity: a case-control study in the Netherlands.
Article in Drug safety, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Drug-Gene Risk Stratification in Patients with Suspected Drug-Induced Interstitial Lung Disease.Drug safety · 2024Observational
- Role of Drug-Gene Interactions and Pharmacogenetics in Simvastatin-Associated Pulmonary Toxicity.Drug safety · 2021Observational
- Vitamin E acetate as linactant in the pathophysiology of EVALI.Medical hypotheses · 2020Article
- HRCT Patterns of Drug-Induced Interstitial Lung Diseases: A Review.Diagnostics (Basel, Switzerland) · 2020Review
- Tamsulosin Associated with Interstitial Lung Damage in CYP2D6 Variant Alleles Carriers.International journal of molecular sciences · 2020Article
- Analysis of drug-induced interstitial lung disease using the Japanese Adverse Drug Event Report database.SAGE open medicine · 2020Article
- Drug-Induced Interstitial Lung Disease: A Systematic Review.Journal of clinical medicine · 2018Review
- Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches.Respiratory research · 2012Review
- Drug induced interstitial lung disease.The open respiratory medicine journal · 2012Article
- Development of cocaine-induced interstitial lung damage in two CYP2C and VKORC1 variant allele carriers.Molecular diagnosis & therapy · 2011Article
- Variant VKORC1 and CYP2C9 alleles in patients with diffuse alveolar hemorrhage caused by oral anticoagulants.Molecular diagnosis & therapy · 2010Article
- Simultaneous interstitial pneumonitis and cardiomyopathy induced by venlafaxine.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e TisilogiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDrug-induced pulmonary toxicity is a serious and expanding problem with often unknown aetiology. Many drugs are metabolized by cytochrome P450 (CYP) enzymes.
objectiveTo establish whether allelic variation in CYP polymorphic genes contributes to variability in drug response and unexpected toxicity.
methodsA case-control study was conducted. The cases consisted of patients with drug-induced interstitial lung disease (DI-ILD; n = 59). Two control groups were used: one group of healthy volunteers (n = 173) and one group of patients with idiopathic pulmonary fibrosis (IPF; n = 110).
resultsOf the patients with DI-ILD 91.5% (54/59) had at least one of the studied variant genes compared with 70.5% (122/173, p < 0.001) of the healthy volunteers and 69.1% (76/110, p < 0.001) of the IPF patients. The percentage of individuals with one or more variant CYP genes was higher in the DI-ILD group. Odds ratios were significantly increased and ranged from 3.25 to 40.8, indicating a significant association between the development of DI-ILD and the presence of one or more variant CYP genes.
conclusionDI-ILD appeared to be associated with the presence of at least one variant CYP allele. This study supports the potential usefulness of personalized medicine by genotyping aiming to improve efficacy, tolerability and drug safety.
Indexed as
Identifiers
19026029What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.